SureTrader
Home > Boards > US OTC > Biotechs >

Bio-Matrix Scientific Group Inc. (BMSN)

BMSN RSS Feed
Add BMSN Price Alert      Hide Sticky   Hide Intro
Moderator: gotinearly, trazbull, vegasdrummer, 1~Eye~Jack!!, Meach2, ADVFN_franknstein
Search This Board:
Last Post: 2/14/2016 1:00:14 PM - Followers: 1049 - Board type: Free - Posts Today: 3
 


 


(Majority-Owned Susidiary of BMSN)
 
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
is a biotechnology company focused on identifying undervalued regenerative medicine applications
in the stem cell space and rapidly advancing these technologies through pre-clinical andPhase I/ II clinical trials.
 

Stem Cell Medicine

 

"Our business model is to acquire and form companies around
undervalued assets identified froma highly focused analysis of issued
patents in regenerative medicinethat have demonstrated proof of 
concept"


 

Dr. Ichim is one of the leading authorities in the
world on stem cell bi
ology.

"A STEM CELL INCUBATOR COMPANY"

With an emphasis on stem cell regenerative medicine

 


 

Our Business Model | Regen BioPharma
                            

our business model 

Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.

 



 

Our Approach | Regen BioPharma

 

           

      REGEN BIOPHARMA AVOIDS WASTE OF "ONE PRODUCT/ONE INFRASTRUCTURE" APPROACH

      In the "Conventional Model", stem cell companies are started with one basic technology, infrastructure is developed around that                       technology, then if the technology fails, significant resources are lost that have been used in the product-specific development
 

             Conventional Model
conventional model

             Regen BioPharma Model
regen model


 



Operational Plan
 

Month 1-2: Assembly of Team:
Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
 
Month 1-4: Inlicensing of Intellectual Property:
The Company having already assessed over 20,000 issued patents and havingcompiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses onissued patents that have already passed preclinical studies but are not under clinical development. -DONE
 
Month 3-6: Interaction with Regulatory Agencies:
Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE
 
Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy.  NEXT UP
 
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.
 
 

 



"At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."

 

 





Regen BioPharma Pipeline

 
HemaXellerate I™ FDA FILING
[Regen BioPharma filed an Investigational New Drug (IND) Application on February 5th, 2013.  Regen BioPharma has received approval from the FDA for the clinical protocol and the product manufacturing information for HemaXellerate I.  On May 9, 2014 Regen BioPharma submitted clarification on animal safety studies that the FDA requested with review anticipated within 30 days.]

HemaXellerate I is a cellular therapy designed to heal damaged bone marrow. HemaXellarate I utilizes a collection of cells harvested from the patient’s own adipose (fat) tissue to repair damaged bone marrow and stimulate production of blood cells . The initial application of HemaXellerate I will be the treatment of severe aplastic anemia, a rare and serious condition in which the bone marrow fails to make enough blood cells: red blood cells, white blood cells, and platelets. In practice, the physician is shipped a kit, which is used to collect adipose tissue. The tissue is sent to a processing facility, and a standardized cellular product is delivered in a ready-to-use manner for administration into the patient intravenously.

**The Company intends to seek Orphan Drug Designation under the Orphan Drug Act of 1983 from the US Food and Drug Administration for HemaXellerate I**

 
dCellVax™
[Regen BioPharma is currently in the preclinical stage of development for dCellVax and plans to file an Investigational New Drug Application in August 2014]

The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO.

The dCellVax therapeutic product uses patents that Regen BioPharma has in-licensed from Dr. Wei-Ping Min coupled with patents in-licensed from Benitec BioPharma.  By utilizing methods covered in both of these patents Regen BioPharma hopes to develop an immune-based, non-toxic cancer treatment initially targeting breast cancer.

HemaXellerate II™
[Regen BioPharma is currently in the preclinical stage of development for HemaXellerate II]

HemaXellerate II is intended to be a universal donor endothelial cell based therapeutic and is intended to be manufactured by obtaining cells from a part of the placenta called the “vascular lobules”. The cells are processed and utilized for the purpose of stimulating bone marrow hematopoetic stem cell repair and proliferation. The mechanism of action for HemaXellerate II is similar to HemaXellerate I whereby the harvested and processed cells would produce growth factors which would mediate the therapeutic effects of the product.

 



Managent Team | Regen BioPharma
 


David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.




Thomas E. Ichim, PhD

Chief Scientific Officer and Board Member

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. Dr. Ichim is a member of Vendevia Group, an innovative venture development organization focused on optimization of value in biotechnology ventures. He is scientific advisor to Orcrist Bio, Entest, and MBVaX. To date he has published 91 peer-reviewed articles and is co-editor of the textbook “RNA Interference: From Bench to Clinical Translation”. Ichim is an ad-hoc editor and sits on several editorial boards. Ichim is inventor on over 30 patents and patent applications. CV

 



Advisory Board | Regen BioPharma

 


Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.



David James Graham White, M.D., Ph.D.

Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

David A. Suhy, PhD

Dr Suhy has a long-term interest in development of shRNA based therapeutics to treat human diseases. He is in the unique position of seeing of directing the research of a RNAi-based therapeutic from its earliest inception until it reaches clinical trials. Development of a shRNA therapeutic against the Hepatitis C virus (HCV) was initiated at Avocel in 2003. Financial constraints caused the company to shutter research operations in 2006.Upon raising venture capital, Tacere Therapeutics acquired the rights to the HCV family of drugs and brought back Dr. Suhy to head the program. Partnered with Pfizer shortly thereafter, this drug is their first foray into gene therapy-based approaches and is the first shRNA program partnered with a large pharma. Given Pfizer’s lack of experience in both areas, Dr. Suhy has played a pivotal role in its development as Tacere has continued to lead the research efforts for advancement of this product into the clinic and has stood side-by-side with Pfizer through all of the regulatory agency meetings.

 


 

Current Business Partners | Regen BioPharma

 
                                                                
                                         
   

 


 


 

                        News and Recent Press Releases:
 

05/12/2014 12:30 Regen Biopharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND...
03/06/2014 14:53 Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Subsidiary, Regen BioPharma, Inc.
12/11/2013 09:35 Regen BioPharma Announces HemaXellerate I (TM) Efficacy Data in Animal Model of Aplastic Anemia

10/31/2013 11:35 Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
10/09/2013 15:11 Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
09/26/2013 08:00 Bio-Matrix Scientific Group's Subisidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I..
09/25/2013 08:30 Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
09/17/2013 10:06 Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
08/16/2013 13:47 Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
08/08/2013 09:47 Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
07/31/2013 14:36 Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I (TM) Clinical Program
06/07/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
05/06/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
04/04/2013 16:09 Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
03/18/2013 09:57 Regen BioPharma Receives IND # From FDA for HemaXellerate
02/26/2013 10:12 Bio-Matrix Scientific Group's Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing...
02/05/2013 10:35 Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I (TM) Stem Cell Drug For Aplastic...
01/24/2013 14:53 Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate (TM) Bone Marrow Failure Product




  





















 



 


 
 
 
(Majority-Owned Susidiary of BMSN)

Overview

Entest BioMedical Inc.(OTCQB: ENTB) develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine.  Of specific interest to us are immunological vaccines for oncology (cancer vaccines) and veterinary clinic acquisitions.  The basis for the majority of our approaches is underpinned by leveraging the body's own reparative / immunological mechanisms - as opposed to using toxic chemicals.

Areas of Focus
 
Currently, Entest is focused on significant therapeutic therapies that show promise for the development of under-served market niches with potential high demand.

 
 

 


Bio-Matrix Scientific Group's Stock Information 

OS 3,079,910,118  (OS accurate as of 09/24/14)
OS 4,232,931,245  (OS accurate as of 06/30/15)
OS 4,889,075,005 (OS accurate as of  12/29/15)
 
Authorized Shares: 8,000,000,000
 

BMSN Transfer Agent:
Securities Transfer Corporation

2591 Dallas Parkway Suite 102

Frisco, Texas 75034

Phone - 469-633-0101

FAX 469-633-0088

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMSN
Current Price
Volume:
Bid Ask Day's Range
Wiki
BMSN News: Quarterly Report (10-q) 02/02/2016 06:08:25 AM
BMSN News: Amended Annual Report (10-k/a) 01/08/2016 01:02:07 PM
BMSN News: Annual Report (10-k) 01/08/2016 06:36:44 AM
BMSN News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 12/30/2015 06:05:52 AM
BMSN News: Current Report Filing (8-k) 12/17/2015 06:05:08 AM
PostSubject
#154293  Sticky Note Regen BioPharma Submits Application to FDA for Orphan gotinearly 01/26/16 09:15:26 AM
#154155  Sticky Note 15.6% - BMSN's ownership in fact has more ADVFN_franknstein 01/08/16 06:40:49 AM
#154034  Sticky Note Important from BMSN 8-K filed on 12/17/2015... stervc 12/23/15 09:40:10 AM
#153431  Sticky Note BMSN..Receives FDA Clearance to Initiate Clinical Trial of HemaXellerate..Boo Nadendla 12/15/15 09:40:48 AM
#152406  Sticky Note RGBP,=SUBSIDIARY=OF=BMSN,=CREATES=CURE=FOR=CANCER? Meach2 08/26/15 08:02:00 PM
#134995  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 06/03/14 05:06:37 PM
#154449   Good one. LaddyMan 02/14/16 01:00:14 PM
#154448   I agree, added 24 million last week and sizzleweed 02/14/16 01:55:13 AM
#154447   $BMSN ~ Bio-Matrix Scientific Group, Inc. due diligence $Pistol Pete$ 02/14/16 01:00:04 AM
#154446   $BMSN Chart http://www.stockscores.com/chart.a $Pistol Pete$ 02/12/16 10:52:04 PM
#154445   We'll run to 3 or 4 before we tebow4ever 02/12/16 07:52:26 PM
#154444   Umm we have made trades at .0001 the Beek 02/12/16 06:24:07 PM
#154443   Reason? bucks2pennies 02/12/16 02:18:09 PM
#154442   Headed toward no bid is my guess. IMO the Beek 02/12/16 02:11:46 PM
#154441   Few .0001s are to be had folks. bucks2pennies 02/12/16 11:40:36 AM
#154440   I'm in that EXACT frame of mind. Agree mrMando 02/12/16 11:30:23 AM
#154439   I am buying at .0002. Averaging down bucks2pennies 02/12/16 11:17:17 AM
#154438   Move up to #12 on the break out konshe 02/12/16 11:07:22 AM
#154437   who are so stupid sell at the bottom. konshe 02/12/16 10:58:34 AM
#154436   You just said a mouthful with that statement. vegasdrummer 02/12/16 10:56:57 AM
#154435   Don't worry I won't be selling at these herbster 02/12/16 10:54:11 AM
#154434   I just re-get in for this stock. I konshe 02/12/16 10:51:57 AM
#154433   I've been in this stock way too long herbster 02/12/16 10:43:48 AM
#154432   Warming, Ready, fly. gap up any day with news. konshe 02/12/16 10:38:02 AM
#154430   Watch and learn ... yeah. ADVFN_franknstein 02/12/16 10:22:04 AM
#154429   Bring it on Go $BMSN! artmaniac 02/12/16 10:12:52 AM
#154428   Hearing explosion news coming. Jobrano 02/12/16 10:11:24 AM
#154427   Gonna see a huge move Jobrano 02/12/16 10:10:57 AM
#154426   Huge signs is going on Jobrano 02/12/16 10:10:33 AM
#154425   BMSN is move up to #18 on break konshe 02/12/16 10:07:22 AM
#154424   Level 2 shows no debt convertors sell. It's konshe 02/12/16 10:04:14 AM
#154423   Ready to break out. This stock never go konshe 02/12/16 10:01:09 AM
#154422   MM are accumulating shares. They sold $20 at konshe 02/12/16 09:57:46 AM
#154421   Can't go down any further except the no bid herbster 02/12/16 09:55:25 AM
#154420   Don't wanna burst your bubbles. But let's do ADVFN_franknstein 02/12/16 09:50:24 AM
#154419   Gap up any day with good news. konshe 02/12/16 09:35:14 AM
#154418   BMSN is #35 on the breakout board. Anything konshe 02/12/16 09:26:16 AM
#154417   Very possible to be buy out. This company konshe 02/12/16 09:15:27 AM
#154416   It is made up to scare potential buyers ADVFN_franknstein 02/12/16 12:54:50 AM
#154415   My prediction. With a half billion buyout, we Sage7243 02/11/16 10:26:39 PM
#154414   Bought 1.2 million at .0002 artmaniac 02/11/16 09:47:01 PM
#154413   The Market is waiting.it's up to the CEO.. sante1 02/11/16 09:02:48 PM
#154412   Not a chance! .10 will never happen! Well the Beek 02/11/16 07:59:28 PM
#154411   I still anticipate a buyout of RGBP that Sage7243 02/11/16 07:47:47 PM
#154410   I haven't sold since then also. Even bought herbster 02/11/16 07:36:37 PM
#154409   Still waiting...haven't sold a share since .0065 Sage7243 02/11/16 06:33:08 PM
#154408   I'd take that haha I'd almost break even tebow4ever 02/11/16 03:35:33 PM
#154407   You mean with the 5 billion OS? Yeah the Beek 02/11/16 01:56:37 PM
#154406   Should have a new revived run from here imo tebow4ever 02/11/16 01:53:58 PM
#154405   There is no information. It is made gotinearly 02/11/16 01:34:31 PM
#154404   Ready for huge Spike ! Jobrano 02/11/16 12:39:16 PM
#154403   where did you have R / S information? sipp 02/11/16 12:34:12 PM
#154402   Got that right. 1/1000???? bucks2pennies 02/11/16 12:10:08 PM
#154401   R/s is inevitable. This will never see .0005 the Beek 02/11/16 11:57:27 AM
#154400   2's obviously cleared out. ADVFN_franknstein 02/11/16 11:03:31 AM
#154399   $BMSN ~ Bio-Matrix Scientific Group, Inc. due diligence $Pistol Pete$ 02/11/16 01:24:45 AM
PostSubject